Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome-Reference-Cited by-同舟云学术

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

Published:2008-10 Issue:9648 Volume:372 Page:1484-1492
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Bercovich Dani,Ganmore Ithamar,Scott Linda M,Wainreb Gilad,Birger Yehudit,Elimelech Arava,Shochat Chen,Cazzaniga Giovanni,Biondi Andrea,Basso Giuseppe,Cario Gunnar,Schrappe Martin,Stanulla Martin,Strehl Sabine,Haas Oskar A,Mann Georg,Binder Vera,Borkhardt Arndt,Kempski Helena,Trka Jan,Bielorei Bella,Avigad Smadar,Stark Batia,Smith Owen,Dastugue Nicole,Bourquin Jean-Pierre,Tal Nir Ben,Green Anthony R,Izraeli Shai

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Pattern of malignant disorders in individuals with Down's syndrome;Hasle;Lancet Oncol,2001

2. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome;Wechsler;Nat Genet,2002

3. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21;Rainis;Blood,2003

4. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis;Vyas;Early Hum Dev,2006

5. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder;Groet;Lancet,2003

Cited by 292 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms;Frontiers in Oncology;2024-07-18

3. Acute lymphoblastic leukaemia;Nature Reviews Disease Primers;2024-06-13

4. Molecular basis of JAK2 activation in erythropoietin receptor and pathogenic JAK2 signaling;Science Advances;2024-03-08

5. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group;Journal of Clinical Oncology;2024-01-10